• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:40:09 AM ET
    $PRAH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PRAH alert in real time by email
    SC 13G/A 1 tv01639-prahealthsciencesinc.htm SCHEDULE 13G/A prahealthsciencesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  PRA Health Sciences Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  69354M108

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  69354M108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    49,730

    7.  SOLE DISPOSITIVE POWER

    6,607,393

    8.  SHARED DISPOSITIVE POWER

    101,748

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,709,141

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.46%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    PRA Health Sciences Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    4130 ParkLake Avenue
    Suite 400
    Raleigh, NC 27612

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    69354M108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    6,709,141

      (b) Percent of Class:

    10.46%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  49,730

    (iii)  sole power to dispose of or to direct the disposition of:  6,607,393

    (iv)  shared power to dispose or to direct the disposition of:  101,748

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $PRAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

      Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e

      3/3/25 8:00:00 AM ET
      $AKYA
      $CMBM
      $CSCO
      $DOMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Radio And Television Broadcasting And Communications Equipment
      Technology
    • DT Midstream Set to Join S&P MidCap 400

      NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.   Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker

      6/28/21 6:07:00 PM ET
      $SPGI
      $DTE
      $ICLR
      $PRAH
      Finance: Consumer Services
      Finance
      Electric Utilities: Central
      Utilities
    • Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

      Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re

      6/23/21 8:01:00 AM ET
      $PRAH
      $MDRX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      EDP Services
      Technology

    $PRAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PRA Health Sciences downgraded by Truist with a new price target

      Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously

      5/10/21 7:22:17 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Credit Suisse reiterated coverage on PRA Health Sciences with a new price target

      Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously

      4/29/21 10:40:10 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PRA Health Sciences downgraded by Baird with a new price target

      Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00

      4/20/21 7:51:16 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    SEC Filings

    See more
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:48:41 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:45:04 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:47:14 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:29:52 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:26:22 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 5:47:14 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

      Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

      5/26/21 7:00:00 AM ET
      $AVXL
      $TMDX
      $PRAH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Commercial Physical & Biological Resarch

    $PRAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PRA Health Sciences, Inc.

      SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 4:27:12 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 10:21:51 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      4/12/21 2:07:51 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care